Ann: Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease, page-127

GREAT ARTICLE @Moreforme

“We have now looked at our own data in lung disease in adults where half the patients had the same kind of inflammation in the lungs as you get with coronavirus, and our cells significantly reduced the inflammation and significantly improved lung function,” Itescu said, noting that he is awaiting emergency use authorization to treat patients under a clinical trial protocol.

"Current therapeutic interventions do not appear to be improving in-hospital survival, and remestemcel-L has potential for use in the treatment of ARDS, which is the principal cause of death in COVID-19 infection.

Itescu said he didn’t know of any other stem cell companies that were doing this.

He said that other companies could try the approach from a research perspective but that Mesoblast has all the patents locked down.

The company’s intellectual property portfolio encompasses more than 1,000 patents or patent applications in all major markets and includes the use of MSCs obtained from any source for patients with ARDS, and for inflammatory lung disease due to coronavirus (COVID-19), influenza and other viruses."

UMMMM GREAT!!!!!!!!

The company is in active discussions with various governments, regulatory authorities, medical institutions and pharmaceutical companies to implement these activities.

Watching and waiting for the approvals and the market to catch on!!!!

CRISIS = OPPORTUNITY